Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease
Article first published online: 3 JUN 2008
© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 28, Issue 6, pages 674–688, September 2008
How to Cite
PANACCIONE, R., RUTGEERTS, P., SANDBORN, W. J., FEAGAN, B., SCHREIBER, S. and GHOSH, S. (2008), Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 28: 674–688. doi: 10.1111/j.1365-2036.2008.03753.x
- Issue published online: 20 AUG 2008
- Article first published online: 3 JUN 2008
- Publication data Submitted 19 April 2007 First decision 9 May 2007 Resubmitted 15 November 2007 Accepted 31 May 2008 Epub Accepted Article 3 June 2008
Background Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the intestine, which frequently require surgery for complications or failure of medical therapy.
Aim To seek evidence and provide direction for clinicians on optimal strategies to enable steroid free remission in inflammatory bowel disease.
Methods Scientific literature was reviewed using MEDLINE with a specific focus on medical therapies for inducing and maintaining remission of CD and UC. The results were discussed at a roundtable meeting to reach a consensus on key issues.
Results Several therapies have demonstrated efficacy for the treatment of active, moderate-to-severe CD and UC. These include agents, which induce remission [corticosteroids, infliximab and adalimumab (CD only)] or maintain remission and spare corticosteroids [azathioprine, mercaptopurine, methotrexate (CD only), infliximab and adalimumab (CD only)]. Wide variability exists in the use of these agents.
Conclusion Treatment strategy algorithms are developed for use of these therapies that maximize remission and minimize corticosteroid dependence in patients with moderate-to-severe CD and UC.